Anti-SUCB2/ SUCLG2/ G-SCS monoclonal antibody

Anti-SUCB2/ SUCLG2/ G-SCS antibody for FACS & in-vivo assay

Target products collectionGo to SUCLG2/SUCLG2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2341-Ab-1/ GM-Tg-hg-MP2341-Ab-2Anti-Human SUCLG2 monoclonal antibodyHuman
GM-Tg-rg-MP2341-Ab-1/ GM-Tg-rg-MP2341-Ab-2Anti-Rat SUCLG2 monoclonal antibodyRat
GM-Tg-mg-MP2341-Ab-1/ GM-Tg-mg-MP2341-Ab-2Anti-Mouse SUCLG2 monoclonal antibodyMouse
GM-Tg-cynog-MP2341-Ab-1/ GM-Tg-cynog-MP2341-Ab-2Anti-Cynomolgus/ Rhesus macaque SUCLG2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2341-Ab-1/ GM-Tg-felg-MP2341-Ab-2Anti-Feline SUCLG2 monoclonal antibodyFeline
GM-Tg-cang-MP2341-Ab-1/ GM-Tg-cang-MP2341-Ab-2Anti-Canine SUCLG2 monoclonal antibodyCanine
GM-Tg-bovg-MP2341-Ab-1/ GM-Tg-bovg-MP2341-Ab-2Anti-Bovine SUCLG2 monoclonal antibodyBovine
GM-Tg-equg-MP2341-Ab-1/ GM-Tg-equg-MP2341-Ab-2Anti-Equine SUCLG2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2341-Ab-1/ GM-Tg-hg-MP2341-Ab-2; GM-Tg-rg-MP2341-Ab-1/ GM-Tg-rg-MP2341-Ab-2;
GM-Tg-mg-MP2341-Ab-1/ GM-Tg-mg-MP2341-Ab-2; GM-Tg-cynog-MP2341-Ab-1/ GM-Tg-cynog-MP2341-Ab-2;
GM-Tg-felg-MP2341-Ab-1/ GM-Tg-felg-MP2341-Ab-2; GM-Tg-cang-MP2341-Ab-1/ GM-Tg-cang-MP2341-Ab-2;
GM-Tg-bovg-MP2341-Ab-1/ GM-Tg-bovg-MP2341-Ab-2; GM-Tg-equg-MP2341-Ab-1/ GM-Tg-equg-MP2341-Ab-2
Products NameAnti-SUCLG2 monoclonal antibody
Formatmab
Target NameSUCLG2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SUCLG2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species SUCB2/ SUCLG2/ G-SCS VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2341
    Target NameSUCLG2
    Gene ID8801,20917,362404,697454,476562,101088732,537713,100063955
    Gene Symbol and SynonymsD6Wsu120e,G-SCS,GBETA,GTPSCS,SCS-betaG,SUCLG2
    Uniprot AccessionQ96I99,Q3MHX5
    Uniprot Entry NameSUCB2_HUMAN,SUCB2_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000172340
    Target ClassificationN/A

    The target: SUCLG2, gene name: SUCLG2, also named as G-SCS, GBETA, GTPSCS. This gene encodes a GTP-specific beta subunit of succinyl-CoA synthetase. Succinyl-CoA synthetase catalyzes the reversible reaction involving the formation of succinyl-CoA and succinate. Alternate splicing results in multiple transcript variants. Pseudogenes of this gene are found on chromosomes 5 and 12. [provided by RefSeq, Apr 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.